CAR-T 治疗急性髓系白血病的临床前进展与机制见解：从靶点迭代到微环境调控

Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.

本综述系统总结了 CAR-T 疗法治疗 AML 的临床前进展及机制基础，聚焦于两大核心瓶颈。

AML 中的 CAR-T 与 CAR-NK 细胞疗法：打破壁垒，规划未来

CAR-T and CAR-NK cell therapies in AML: breaking barriers and charting the future.

急性髓系白血病治疗的靶向与表观遗传治疗

Targeted and epigenetic therapies for acute myeloid leukemia treatment.

CRISPR/Cas9 工程化通用型 CD123/B7-H3 串联 CAR-T 细胞治疗急性髓系白血病

CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia.

该研究结果解决了急性髓系白血病治疗中的肿瘤抗原逃逸问题，规避了与自体 CAR-T 细胞疗法相关的某些局限，并为急性髓系白血病的治疗提供了新的见解和策略。

CAR-T 细胞治疗在急性髓系白血病中的突破：ASH 2024 更新

Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024.

选 BE 还是选 PE：先导编辑器为基于表位编辑的免疫治疗提供更多选择

To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy.

表位先导编辑保护造血细胞免受急性髓系白血病 CD123 免疫治疗影响

Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia.

CAR-T 治疗急性髓系白血病的最新进展

Recent advances in CAR-T therapy for the treatment of acute myeloid leukemia.

嵌合抗原受体（CAR）修饰 T 细胞治疗急性髓系白血病：局限与展望

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations.

表位工程化的人类造血干细胞可免受 CD123 靶向免疫疗法的攻击

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy.